Regulatory Approval Process for Veterinary Drugs – A Global Perspective M. R. Srinivasan and P. Sriram Laboratory Animal Medicine, Centre for Animal Health.

Slides:



Advertisements
Similar presentations
The Drug Discovery Process
Advertisements

Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.
T. Fujita OIE Regional Representative for Asia and the Pacific
Dr. Michael E. Oehlsen International Policy Analyst International Programs Team - Office of the Director Center for Veterinary Medicine Food and Drug Administration.
Chemistry, Manufacturing, and Controls (CMC) and Good Manufacturing Practices (GMPs): The Big Picture of a Long-term Commitment Elizabeth Pollina Cormier,
Regulation and Safety Assessment of Novel Foods in Canada William Yan, Ph.D. Office of Food Biotechnology Health Canada.
Introduction to Regulation
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
What Do Toxicologists Do?
Stefan Franzén Introduction to clinical trials.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
1 FDA Thailand By HIV Module/Marketing Group Mr. Manaswee Arayasiri.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
1 The FDA and Animal Drug Compounding Neal Bataller, DVM FDA/Center for Veterinary Medicine AAVPT 14 th Biennial Symposium, May 16-17, 2005, Rockville,
Tanzania, August, 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Guidelines and Tools available TRS 937 and BTIF (Bioequivalence Trial Information Form)
REGISTRATION OF MEDICINES & PROGRESS WITH RESTRUCTURING THE MCC 1.
Towards a global plan to fight against bioterrorism in synergy with Russian Federation Novosibirsk
The Drug Development Process
CVM’s Procedure for Setting Tolerances
Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
What is ICH? ICH is a joint initiative involving both regulators and research-based industry representatives of the EU, Japan and the US in scientific.
Stefan Franzén Introduction to clinical trials.
REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Exploratory IND Studies
SFDA-2007 الهيئة العامة للغذاء والدواء Bioequivalence Studies of Generic Pharmaceutical Products Workshop-Day II Introduction and workshop Objectives By:
Important informations
1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines:
TECHNICAL REQUIREMENTS FOR MINOR APPLICATIONS E MOKANTLA 3 SEPTEMBER 2013.
DEPARTMENT OF HEALTH Medicines Regulatory Affairs
Developing medicines for the future and why it is challenging Angela Milne.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Privacy Symposium / HIPAA Summit
GMP- A Regulatory Perspective. Regulatory Perspective in entering Global Pharma Markets.
Suzanne Sechen, Ph.D. Leader, Ruminant Drugs Team Division of Production Drugs Office of New Animal Drug Evaluation, CVM Labeling Issues.
Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.
JMAFF (Chair of Biologicals Quality Monitoring EWG)
VICH General Principles and current update of VICH Outreach Forum activity 1.
-What is VICH, History and Objectives Hervé MARION, DVM VICH Secretariat.
1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.
E-Clinical
The Benefits of VICH to VICH Member Countries and Regions DONALD A. PRATER, DVM Director, U.S. FDA Europe Office Office of International Programs Office.
Regulation of Generic Animal Drugs in the United States
Link between legal framework of VMP regulation and VICH GLs in Japan Takashi Kozasa DVM Ministry of Agriculture, Forestry and Fisheries Government of Japan.
INDEX WHAT IS ICH ? HISTORY INITIATION INTRODUCTION TOPICS QUALITY GUDILINES.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
How to get involved in VICH Dr. Allen Bryce Independent consultant Canberra, Australia VICH Workshop: Dar Es Salaam, Tanzania – 24.
The process of drug development. Drug development 0,8 – 1 mld. USD.
Waiving TABST for vaccines Argentina: Not an allowed procedure today Require batch safety tests in laboratory animals, repeated by authorities Currently.
Tanzania, August 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Bioequivalence dossier requirements for the prequalification project WHO Training Workshop.
1 1 Topics “out of the scope of VICH” Brigitte Boenisch IFAH-Europe 2 nd VICH Outreach Forum Meeting Washington, 19 th /20 th February 2012 – how and by.
Drug Development Process Stages involved in Regulating Drugs
RAC Regulatory Affairs Certification
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
VICH General Principles and
Recent Evolution of New Drug Review and Approval System in Korea
נמטוציטים משושנת ים Eli. S Lec. No.2.
Regulatory– Terms & Definitions רגולציה - מונחים והגדרות
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
American Society for Quality Region 5 Quality Conference
Data Requirements for Old Products/Generics, Bioequivalence
The Lifecycle of Pharmaceutical products
Waiving Target Animal Batch Safety Testing for vaccines
What is ICH? ICH is a joint initiative involving both regulators and research-based industry representatives of the EU, Japan and the US in scientific.
GL50(R)- HARMONISATION OF CRITERIA TO WAIVE TARGET ANIMAL BATCH SAFETY TESTING FOR INACTIVATED VACCINES FOR VETERINARY USE ( May 2017) GL55- HARMONISATION.
SID & GP MINPROMTORG OF RUSSIA Corporate Communication Center
Control of Veterinary Drugs in South Africa
NIGERIAN REGISTRATION SYSTEMS OF VETERINARY MEDICINAL PRODUCTS :
Presentation transcript:

Regulatory Approval Process for Veterinary Drugs – A Global Perspective M. R. Srinivasan and P. Sriram Laboratory Animal Medicine, Centre for Animal Health Studies, Tamil Nadu Veterinary and Animal Sciences University, Madhavaram Milk Colony, Chennai – Regulatory Approval Process for Veterinary Drugs – A Global Perspective M. R. Srinivasan and P. Sriram Laboratory Animal Medicine, Centre for Animal Health Studies, Tamil Nadu Veterinary and Animal Sciences University, Madhavaram Milk Colony, Chennai – Introduction  Similar to the human pharmaceutical industry, innovation is essential to the existence of animal health companies.  The development of new vet drugs take 5–15 yrs  More than US$100 million to advance an animal health drug from initial concept to market.  Total Indian animal health market ~$212 Mn, 1/100 th of world market (Source: Express Pharma, May 2008) with largest livestock population in the world  All animal health drugs (excluding medical devices) are required to be approved by an appropriate regulatory agency prior to marketing.  The goal is to ensure quality, safety & effectiveness Source: Vetnosis Phases in New Veterinary Drug Development: Discovery Phase: Unmet animal health needs & satisfactory return on investments (market assessment)  Patentability  Ease of manufacture  Initial PoC – In Vitro & In Vivo studies  Preliminary ADME  API Stability  Target animal safety and Preliminary toxicology studies Development Phase: Further characterisation of drug substance  Detailed ADME Studies, plasma & tissue bio-analytical methods, 14 C studies  Manufacture potential; scale-up batches  Business decision to advance the lead to more expensive registration phase  Contact regulatory agency & open INAD file Registration Phase: Fulfil the requirement of NADA application  All Studies in GLP, and GCP mode  GMP API material  Robust validated analytical & bio-analytical methods  Effectiveness, Target animal safety, CMC, Environmental assessment, Human Food safety, FoI summary, and labelling Approval Process – United States of America New animal drugs are approved and regulated by FDA’s Center for Veterinary Medicine (CVM) AAVPT Veterinary Drug Regulatory Life Cycle Online Course – Free cess/ucm htm Case Study: A new antibiotic“drug X” for Bovine Respiratory Disease(BRD) Discovery & Development Phase – Drug X Demonstrate acceptable activity against BRD pathogens: In vitro assay- Mannheimia hemolytica, Pasteurella multocida, etc. :‘hits’ Discovery & Development Phase – Drug X Demonstrate acceptable activity against BRD pathogens: In vitro assay- Mannheimia hemolytica, Pasteurella multocida, etc. :‘hits’ Bovine model of induced BRD: In vivo efficacy, No acute target animal toxicity at efficacy dose ADME studies - IV/SC PK study Bio-analytical method development in plasma & tissue “Truck & shoot” study – mimic transportation of bovines 14 C study – Preliminary total residue study Preliminary target animal safety studies – acutely safe API Manufacturing & finalization of formulation Registration Phase Open INAD file with ONADE office of FDA’s CVM – Discuss development plan of new animal drug Five Major Technical Sections Studies are conducted as per V-ICH guidelines ( Harmonised guidelines for 3 regions, ie. USA, EU & Japanwww.vichsec.org Five Major Technical Sections Studies are conducted as per V-ICH guidelines ( Harmonised guidelines for 3 regions, ie. USA, EU & Japanwww.vichsec.org 1. Effectiveness: in vitro study, study in laboratory animals, study in target species, Field study, bioequivalence study 4. Chemistry, Manufacturing and Control (CMC): Describes the plan for making the drug a)What ingredients will be used to make the drug b)Where the ingredients will come from c)Where the drug will be made d)How it will be made & packaged e)How it can be stored (under what conditions) and f)How long it can be stored (determine expiration date) 4. Chemistry, Manufacturing and Control (CMC): Describes the plan for making the drug a)What ingredients will be used to make the drug b)Where the ingredients will come from c)Where the drug will be made d)How it will be made & packaged e)How it can be stored (under what conditions) and f)How long it can be stored (determine expiration date) 5. Environmental Impact: a)Categorical Exclusion b)Environmental introduction and fate studies c)Environmental effects studies d)Environmental assessment 5. Environmental Impact: a)Categorical Exclusion b)Environmental introduction and fate studies c)Environmental effects studies d)Environmental assessment New Animal Drug Application Approved for marketing Approval Process – India  Drugs and Cosmetics Act and Rules 1945 and revised on 2003  No separate guidelines for approval of Veterinary medicine  For Vet Biological follow Schedule F(1)-Purity, Strength & Quality  For other standards – follow British Pharmacopoeia (Veterinary) Schedule F(1) Part I: Vaccines Bacterial Viral Part II: Antisera Antibacterial sera Antiviral sera Antitoxin sera Part III: Diagnostic Antigens Conclusion  Veterinary medicine market in India – very small Vs world market  Drug Discovery and Development – costly affair, 5-15 yrs  Veterinary medicine approval process well regulated globally  Indian regulatory process for Vet medicine  human medicine  A global perspective on regulatory approval process is essential  to change regulatory process in India – ‘at par’ globally  to develop expertise in regulatory studies  to attract top R&Ds to India – tap the resources 2. Human Food Safety: a)Toxicology: To determine ADI – Mutagenicity, 90-day study in rodent and non-rodent, Reproductive toxicity study & Teratology study b)Residue Chemistry: Using ADI, set the tolerance limit & set the withdrawal time c)Microbial food safety: Bacterial resistance to antibiotics and it’s impact on public health d)Regulatory Method: CVM ensures appropriate and accurate testing methods in human food safety studies 2. Human Food Safety: a)Toxicology: To determine ADI – Mutagenicity, 90-day study in rodent and non-rodent, Reproductive toxicity study & Teratology study b)Residue Chemistry: Using ADI, set the tolerance limit & set the withdrawal time c)Microbial food safety: Bacterial resistance to antibiotics and it’s impact on public health d)Regulatory Method: CVM ensures appropriate and accurate testing methods in human food safety studies 3. Target Animal Safety: Tolerance study, Reproductive Safety Study, Animal Class Safety (e.g., young, geriatric), Special Cases (specific breeds) Recommendations of the “Confluence of Veterinary Regulatory Reforms in India” – 6 th Oct 2012  A Separate Veterinary Drug Control Authority  Drug Consultative Committee – Vet. Drugs & Formulations (VDFs)  New Drug Approval Committees – include Vets for VDFs  Veterinary Pharmacopeia – required  Vets as Veterinary Drug Officers/Inspectors for VDFs at State level  Veterinary Drug Portal & Harmonization of Standards  Govt. policy: pro-development & attract industry and investment